Life Extension Skin Care Sale

Prostate Cancer Prevention

Prostate Cancer Prevention Controversy

By William Faloon

An editorial I generated for the May 2013 issue of Life Extension magazine® received quite a bit of feedback and critique.

Some Life Extension® members said it should be a mandatory part of physician education. Others raised concerns about the use of the PSA blood test as a screening tool, why I suggest Avodart® for certain men, and why drugs were mentioned since there are nutrients that function via similar mechanisms.

The most impressive critique came from Patrick C. Walsh, MD, who may be the most renowned prostate cancer expert in the world. Dr. Walsh was involved in identifying the genetic characteristic of hereditary prostate cancer and pioneered “nerve-sparing” surgery. I have urged hundreds of prostate cancer patients to travel to Johns Hopkins to have Patrick Walsh perform their surgery, as I consider him the finest in the world.

risk of aging  

So when Dr. Walsh writes us, I pay attention, and Life Extension members should be informed that there are credentialed individuals that are against using drugs in the class of Avodart® for cancer pre­vention purposes.

Shortly after my 2013 editorial was published, the American Urological Association issued revised guidelines for PSA screening. They now say PSA screening should be mostly considered only for men aged 55-69 (AUA 2013). We vehemently disagree with this new recommendation and chastise this group for not emphasizing the need to devise safer and more efficient ways of performing prostate diagnostics.

To emphasize the seriousness of all this, the chart titled “A Risk of Aging” shows the spiraling incidence of pros­tate cancer that occurs as men age. Autopsy results reveal that 85% of men have atypical cells in their prostate glands and 1 in 4 has cancer (Billis 1986). While many men with atypical lesions or even malignant cells in their prostate do not ever progress to clini­cal disease, aging men cannot ignore this problem.

digital rectal exam  

The public still accepts absurdly short life spans. We at Life Extension do not and that is just one reason why our position on prostate cancer differs from the mainstream.

There is something to be said about attending live lectures as opposed to staying glued to our computer/TV screens. A good speaker can make an impact that you may forever remember.

I’ll never forget a lecture I attended in 1977 at a South Florida condominium social hall. The place was packed with retirees. The lecturer was over age 80 and passionately urged all men to visit a urologist once a year for a digital rectal exam. He began by reading a long list of the names of the many mem­bers of his retirement commu­nity who had suffered agonizing deaths from metastatic prostate cancer.

The lecturer understood that a digital rectal exam would not detect all prostate cancers, but he knew it could save lives. If the PSA blood test had been available at that time, I can only imagine how feverish this benevolent speaker would have been in advocating PSA tests to his fellow men.

Move forward 35 years and the federal government and some mainstream medical groups are recommending against PSA screening, which is more reliable than digital rectal exams, though both ideally should be done annually (AUA 2013; Moyer 2012).

What Makes Prostate Cancer Different?

Prostate cancer is unusual in that it has a blood marker called prostate-specific antigen (PSA) that can facilitate early detection, thereby enabling therapies to be employed before cancer spreads to regional lymph nodes or distant metastases occur (Catalona 1994).

With the advent and wide­spread use of PSA screening, an argument can be made based on a large human study that huge numbers of men could be spared agonizing deaths from metastatic prostate cancer (Bokhorst 2013; USDC 2012). The earlier diagnosis of prostate cancer, how­ever, must be put into context of the individual patient to ascertain which men need to be treated and which men are reasonable can­didates for active surveillance or “watchful waiting.”

The journal European Urology published a study in 2013 con­ducted on nearly 35,000 men aged 55-69 (Bokhorst 2013). This data came from the European Randomized Study of Screening for Prostate Cancer, a major, robust study examin­ing the impact of PSA screening over a median period of 13 years on prostate cancer mortality. The eye-opening conclusion was that men who underwent repeat­ed PSA screening were 51% less likely to die from prostate cancer than men who did not undergo screening (Bokhorst 2013). If the statistics from this study are applied to the entire population of men aged 55-69 in the United States, PSA screening could potentially save over 80,000 lives in a 13-year period (USDC 2012).

The United States Preventive Services Task Force (USPSTF) published a report in 2012 rec­ommending that men stop under­going PSA screening (Moyer 2012).

Life Extension disagreed with the USPSTF recommendation, particularly as it relates to our members to whom we are stead­fastly committed. We know that in the absence of PSA screening, prostate cancer will once again be diagnosed at an advanced stage, when there is painful bulky dis­ease and only a small chance of curative therapy.

The widespread use of PSA testing beginning in 1987 enabled doctors to identify prostate can­cer at a greatly reduced stage of disease (NCI 2012). If the dictum of the USPSTF is followed, a major advance in medicine will be erased.

The Staggering Statistics

Here is what the American Cancer Society says about pros­tate cancer in the United States (ACS 2013d):

  • More than 238,000 new cases of prostate cancer are diagnosed yearly (based on 2013 data).
  • Over 29,000 men die of prostate cancer yearly (based on 2013 data).
  • About 1 man in 6 will be diagnosed with prostate cancer during his lifetime.
  • The average age at diagnosis is 67.
  • Prostate cancer is the sec­ond leading cause of cancer death among American men.
  • About 1 man in 36 will die from prostate cancer.

If prostate cancer were an infectious illness, there would be widespread panic. To put this in perspective, HIV infected less than 50,000 Americans in 2011 (CDC 2013a).

In 2013, the United States Preventive Services Task Force urged all Americans to undergo routine HIV screening (USPSTF 2013).

Decline in prostate cancer mortality  

There are valid reasons for HIV screening, but almost five times more Americans are diagnosed with prostate cancer each year compared to HIV (ACS 2013d; CDC 2013a). The same gov­ernment-funded Task Force that suggests universal HIV screening does not want aging men to ben­efit from early detection of pros­tate cancer. They maintain that the treatment is worse than the disease. They confuse the mes­sage conveyed by the PSA with the judgment and actions of phy­sicians who too often are pro­grammed toward invasive and expensive therapies.

Do we toss out the baby with the bath water, so to speak, because physicians are not taking the time, or possibly do not have the exper­tise to advise patients soundly? The actions of the USPSTF and the American Urological Association should be to fix the deficiency of the physician with strict guide­lines, just as was done in the 1980s to alter the routine use of the rad­ical mastectomy performed in almost every woman diagnosed with breast cancer (Ghossain 2009).

The United States Preventive Services Task Force (USPSTF) prefers aging men wallow in igno­rance concerning their prostate health, which within the next decade will send death rates spiral­ing upwards. The USPSTF clear­ly wants aging men to bury their heads in the sand and not concern themselves about prostate cancer.

The hard statistics showing more than 238,000 newly-diag­nosed prostate cancer cases annu­ally proves otherwise (ACS 2013d). While the USPSTF recommendations will save government health programs billions of dollars in the short term, there will be catastroph­ic long term costs to pay when record numbers of men who could have been cured instead develop metastatic disease.

Why Life Extension Members Are Different

There are factors that influ­ence mainstream recommenda­tions that do not pertain to Life Extension members. The typi­cal American male over age 60 is remarkably unhealthy, often suffering multiple underlying maladies relating to metabolic syndrome and other pathologies called “co-morbidities” (Ervin 2009). This is indicative of a state of disease in the biologic environment of the patient.

A frank diagnosis (or indication) of prostate cancer should act as an early warning that something is amiss in the patient’s overall health and that further attention is war­ranted to various systems. Thus a diagnosis of prostate cancer need not be equated with invasive proce­dures such as radical prostatecto­my, radiation therapy, cryosurgery, high-intensity focused ultrasound, or androgen deprivation therapy, but with a call to the patient and physician to be alert to pathologic states that if corrected can stabilize or repair some or all of the systems that are amiss.

One reason the USPSTF believes that PSA screening should be halted is that so many men are already in such poor health they are likely to die of some other cause before pros­tate cancer becomes clinically relevant (Moyer 2012).

Prostate cancer deaths

Huge Decline in Prostate Cancer Deaths Since Advent of PSA Screening

This is the opposite of Life Extension members, who go to extraordinary efforts to slow aging and protect against degenerative disease. It would be irrational for healthy Life Extension members to stop PSA screening merely because their age group on aver­age is in such poor overall health.

Few doctors today have com­prehensive programs designed to reverse multiple underlying fac­tors that lead to clinically-diag­nosed prostate cancer. The typical aging person does not know about lifestyle changes, drugs, and nutrients that may keep an indo­lent cancer confined to the pros­tate gland.

Life Extension members have long been armed with this infor­mation and have access to health advisors to help guide them to more effective ways of working with their physician to improve their odds of keeping low-grade prostate cancer, or indications of low-grade prostate cancer (such as rising PSA), under control. This protocol is dedicated to reminding mem­bers and alerting the public about these novel approaches to disease prevention.

Most urologists believe when PSA reaches a certain level that their only choice is to perform needle biopsies. They often overlook existing tests, such as testing and properly analyzing blood results of free PSA percentage, PSA den­sity, and PSA velocity, along with other diagnostics such as PCA3 urinary test and advanced non-invasive techniques that can pro­vide additional insight that may reduce the need for invasive proce­dures (Vessella 2000; Lieberman 1999; Stephan 2005; Loeb, Carter 2013; Hessels 2009). Urology patients are not always made aware of these non-invasive choices, and especially of the importance of measuring the PSA rise over time (PSA velocity) to help ascertain if prostate biopsy is warranted.

What clearly separates Life Extension members from the general public, however, are the aggressive steps we take to achieve meaningful extensions of our healthy life spans. Those advising against PSA screening are largely “writing-off” men over age 70.

Life Extension male mem­bers need to ensure their prostate health is assessed and main­tained at an optimal level for the many decades of extended life they expect.

American Urological Association Capitulates

When the United States Preventive Services Task Force suggested that aging men stop PSA screening altogether, the American Urological Association disagreed. About a year later, the American Urological Association issued revised guidelines that will sharply reduce the number of PSA screenings performed (AUA 2013; Pollack 2012; Allard 2012). And other professional groups have issued similar opinions (Qaseem 2013).

The latest recommendation from the American Urological Association (AUA) is for men over age 70 to avoid PSA screening (AUA 2013). The AUA is essentially saying that once you move past age 70, your life span is too short to bother with.

The American Urological Association is also writing off men aged 40-54 for prostate screening because of the relative low incidence of cancer in this group compared to men over 54 (AUA 2013). This is a tragedy as it condemns younger men who do develop prostate cancer to probable death. Earlier diagnosis provides a huge advantage when attempting cura­tive therapy. Just ask Prostate Cancer Foundation Chairman Michael Milken, who insisted on a PSA test at age 46 and dis­covered he had prostate cancer in time to benefit from curative therapy (Moore 2005).

On the flip side are famous peo­ple like Frank Zappa, Telly Savalas, Bill Bixby, and other younger men who likely could have identified their prostate cancer earlier had they undergone PSA screening (PCCNC 2013). These men probably had rising PSA levels long before metastatic disease manifested.

Overlooking More Efficient Procedures

In recommending more limit­ed PSA-screening, the American Urological Association is tacitly admitting that conventional diag­nostic and early treatment of pros­tate cancer is so inadequate, or performed so incompetently, that it’s better to wait for full-blown metastatic disease to manifest. Once advanced stage prostate can­cer develops, however, treatments are seldom curative.

Instead of looking at physi­cians who are diagnosing and treating early stage prostate can­cer using less invasive procedures and then emulating these skilled artists, the American Urological Association has apparently caved in to accepting and promoting mediocrity within their profession.

A big problem is that most urol­ogists are not properly assessing PSA results, nor are they efficient­ly implementing further diagnostic and treatment protocols. And on the other end of the spectrum are the many men who are promptly sent for ultrasound-guided biop­sies after one PSA elevation. And again, to add insult to injury, the biopsies are often not ones tar­geted to abnormalities within the prostate but merely targeting the prostate as a gland.

It is one issue to biopsy an ultrasound lesion that may rep­resent the needle in the haystack, but it’s another issue, and a sad one at that, when it is the hay­stack that is the target. You know that this is the case when a man has had 2, 3, or 4 prostate biopsies showing no cancer cells, and then he is referred, finally, to a compe­tent physician who uses excellent ultrasound equipment to directly target suspicious lesions within the prostate gland.

In these cases, it seems the diagnosis is magically made; but it’s not magic, it is just an issue of a far higher degree of compe­tence. All men are not equal in talent and all equipment is not of the same quality. The unfortunate outcome is that too many aging men are being subjected to need­less and incompetently admin­istered invasive procedures that sometimes result in unnecessary suffering and premature death.

Instead of recommending that medical professionals upgrade their evaluation and treatment protocols to deliver state-of-the-art technology, the United States Preventive Services Task Force suggests that aging men not undergo PSA screening at all, while the American Urological Association limits its recommen­dation for PSA screening mostly to men aged 55-69 (AUA 2013).

The media treats these author­itarian groups as being virtually infallible.

Prostate Cancer Not an Isolated Disease

A common mistake made by doctors and patients is thinking that prostate cancer manifests in isolation from other pathological events occurring as a person ages. This is not the case.

Research shows that other serious pathological conditions are frequently seen in prostate cancer patients (Post 1999). These factors involved in prostate malignancy can adversely impact other parts of the body (Howcroft 2013).

For example, Life Extension has shown one way prostate can­cer and coronary atherosclerosis are related is that they are both influenced by the breakdown of bone (Faloon 2009). As an aging man devel­ops osteoporosis, excess calcium released into the blood contributes to arterial calcification (Faloon 2009). What’s lost in the bone ends up in the coronary arteries and other major vessels of the body (Faloon 2009; Demer 2004).

These atherosclerotic lesions are not vascular “cal­cifications” but bone growth or osteogenesis (Demer 2004; Demer 2009; Abedin 2004). Bone breakdown also releases growth factors into the blood that promote the proliferation of what may have been indo­lent prostate cancer cells (Patterson 2010). Therefore, it should come as no surprise that nutrients that prevent bone loss such as vitamin K2 also inhibit vascular calcification (Beulens 2009; Fodor 2010).

PSA screening thus pro­vides an important clue of a man’s overall health, with the advantage of identify­ing problems early enough to take effective corrective actions. That’s a LOT of bene­fit for assessing one’s prostate gland once a year utilizing PSA blood testing.

Where’s the Accountability?

The level of medical com­petency directly affects the quality and quantity of the lives of others, yet there is not enough monitoring of patient outcomes.

When it comes to treating prostate disease, there needs to be a reporting of serious side effects such as inconti­nence, impotence, and major blood loss or urethral stric­tures after a urologist performs a radical prostatectomy.

This kind of accountabil­ity is relatively non-existent in today’s bureaucratic medi­cal environment, though the Internet may eventually enable patients to assess the degree of medical competency of a physician they entrust their life to.

What Makes Cancer Cells Propagate?

When designing prevention and treatment strategies, Life Extension focuses on underlying mechanisms of disease that are fueled by specific biological fac­tors in the body. This is not perfect science however because you can block one factor involved in tumor development, and cancer cells will use other growth-promoting vehicles to progress.

What we seek to do is stay two steps ahead of the cancer by cut­ting off its many growth promoters and pathways used to escape eradi­cation. For instance, we know that dihydrotestosterone (DHT) pro­motes prostate cell growth (pro­liferation) (Wen 2013). This growth affects both benign prostate cells as well as cancerous ones. In the context of a man with prostate cancer, a serial rise in PSA is circumstan­tial evidence that the tumor cell population is increasing. Such an increase in PSA is not only of importance insofar as prompting investigations to rule out pros­tate cancer. We have evidence that PSA breaks down natural barriers that keep isolated tumor cells con­fined to regions within the pros­tate gland. Remember that PSA is a serine protease, an enzyme that breaks down proteins (Pezzato 2004). One such containment protein degraded by PSA is the extra-cellular matrix, i.e., the natural barrier that may confine cancer cells within the prostate gland.

But suppressing DHT alone is not a total solution. There are other prostate tumor growth pro­moters such as insulin, estrogen, prolactin, transforming growth factor beta (TGF-1 and TGF-2), and vascular endothelial growth factor (VEGF) that also should be brought under control (Cox 2009; Singh PB 2008; Giton 2008; Dagvadorj 2007; Tu 2003; Ling 2005; Häggström 2000). Fortunately, many of the nutrients Foundation members already take can help suppress growth factors used by prostate cancer cells (and other cancers) to proliferate (Meyer 2005; Ripple 1999; Yan 2009; Hussain 2003; Giovannucci 1995; McLarty 2009; Liang 1999; Singh RP 2008; Smith 2008; Xing 2001).

There are other mechanisms involved in the evolution of a prostate tumor such as 5-lipoox­ygenase (5-LOX) (Gupta S 2001; Matsuyama 2004; Ghosh 1997) and cyclo­oxygenase-2 (COX-2) (Xu 2008) that can be markedly improved by dietary changes, along with curcum­in (Bengmark 2006; Lantz 2005), fish oil (Taccone-Gallucci 2006; Calder 2003; Norrish 1999), boswellia (Safayhi 1995), aspirin (Salinas 2010), Zyflamend® (Bemis 2005; Yang P 2007; Capodice 2009; Huang 2012; Sandur 2007), and prescription COX-2 inhibitors like Celebrex® (Harris 2009; Pruthi 2006).

Genetic factors involved in prostate cancer initiation and promotion may be favorably modulated by taking relative­ly high doses of vitamin D (Chen L 2009; Flanagan 2006). Hormonal influences like prolac­tin and insulin can benefit from using prolactin-suppressing drugs like cabergoline (Dostinex®) (Webster 1992) or Lisuride (Bohnet 1979) and the insulin-sup­pressing drug metformin (Clements 2011; Hitron 2012; Wright 2009).

The overriding goal in reversing any cancer is to induce favorable changes in the genes that regu­late cell proliferation and apop­tosis (cell destruction). We know that nutrients like curcumin (Teiten 2010; Shishodia, Singh 2007; Reuter 2011), genistein (Chen 2011; Lakshman 2008; Davis 1998; Davis 1999), fish oil (Berquin 2007; Deckelbaum 2006), and vita­min D (Krishnan 2003; Mantell 2000) favorably affect genes involved in carcinogenesis, as do drugs like aspirin (Yoo 2007; Kim 2005), metfor­min (Jalving 2010; Avci 2013; Isakovic 2007), finasteride (Proscar®) (Luo 2003), and dutasteride (Avodart®) (Schmidt 2009).

THE WHOLISTIC NATURE OF HEALTH IN RELATION TO PROSTATE CANCER

digital rectal exam

As we learn more about specific health issues we see evidence of the interconnectivity of all key processes involved in mind and body functions. This should come as no surprise since this phenomenon characterizes all living entities, from the atom to the universe.

Importance of Food Choices

What one eats (and doesn’t eat) makes a huge impact on whether prostate cancer ever develops (Miano 2003; Itsiopoulos 2009).

Healthier eating patterns also improve the odds of treatment success (Ornish 2008; Kenfield 2007).

A rising PSA level or prostate cancer diagnosis can be the signal that it’s time to switch what you eat more towards a Mediterranean diet that focuses on fish instead of red meat, whole vegetables instead of glucose-spiking starches/sug­ars, foods cooked at lower tem­peratures, and reduced intake of omega-6 fats (Ferris-Tortajada 2012; Kenfield 2013; Sofi 2008).

Those who pioneered aggres­sive dietary changes to help treat cancer were decades ahead of their time. While it’s unlikely that aggressive dietary alterations will cure clinically diagnosed prostate cancer, there are strong mecha­nistic values to consuming foods/beverages that suppress prostate cancer proliferation (like cruci­ferous vegetables [Xiao 2003; Garikapaty 2005; Srivastava 2003] and green tea [Chuu 2009; Thakur 2012]) as opposed to continuing to eat foods that have been related to higher prostate cancer risk such as red meat (Punnen 2011; Michaud 2001; Richman 2011), starches and sug­ars (Bidoli 2005; Freedland 2009), excess dairy (Michaud 2001; Song 2013; Chan 2001; Gao 2005), and excess omega-6 fats that contrib­ute to a high omega-6:omega-3 ratio (Williams 2011; Masko 2013).

Vitamin D Decreases Gleason Tumor Score

If a needle biopsy of the prostate detects a malig­nancy, it will be graded with a Gleason score num­ber as follows:

Under 7(low-grade): Slow growing and not likely to be aggressive (SJPHS 2013). Low-grade prostate cancers are seldom the cause of death in men over age 70, especially those that are in poor health (Stangelberger 2008). Low-grade are the majority of prostate tumors found and the ones where “watchful waiting” is often employed in lieu of radical procedures (Stangelberger 2008; Gofrit 2007).

Over 7 (high-grade): Fast growing, aggressive tumors that require intervention such as radical pros­tatectomy, radiation, androgen ablation, etc (SJPHS 2013). High-grade prostate tumors make up less than 15%* of newly diagnosed prostate cancers (Gofrit 2007).

*Caveat: Errors in the pathology lab can result in lethal mistakes, such as issuing a low Gleason score to a high-grade tumor. These errors are discovered when a radical prostatectomy is performed and it is found to have a Gleason score of 8-10 as opposed to a 6 Gleason score found in the biopsied specimen (Carter 2012).

A study published in 2012 evaluated a group of men with early-stage prostate cancer who received a 4,000 IU vitamin D3 supplement each day for a year (Marshall 2012).

Mean 25-hydroxyvitamin D blood levels at base­line were 32.8 ng/mL and increased to 66.2 ng/mL after vitamin D supplementation (Marshall 2012).

After one year, 55% of the men showed a decrease in tumor-sensitive biopsies or a decrease in the Gleason tumor score. An additional 11% showed no change (meaning the cancer had not progressed).

The study also showed that over time, supplemen­tation with vitamin D3 led to a decrease in the num­ber of positive cores taken during prostate biopsies. This is in stark contrast to the untreated control group who experienced an increase in the number of posi­tive cores on repeat biopsies (Marshall 2012).

Only 34% of men taking vitamin D progressed compared to 63% of the control group. This repre­sents a 46% reduction in the number of men who moved to advancing disease, indicating powerful effects of taking 4,000 IU/day of vitamin D for one year.

The men in this study had not received any other treatment than vitamin D and all were in an active surveillance program that carefully measured dis­ease progression or regression.

This study showed that just one intervention (4,000 IU/day/vitamin D) was able to reverse the clinical course of disease in a significant percentage of these prostate cancer patients.

This study helps validate the importance of PSA screening. Had these men not known they had early-stage prostate cancer, they would not have known to take vitamin D, and their disease would have likely progressed until symptoms such as bone pain manifested.

The section of this protocol titled, “Impact of Diet on Prostate Cancer Risk and Mortality” describes foods that promote prostate cancer and which ones protect against it. We explain how consuming the wrong foods can fuel prostate cancer growth, while following healthy dietary choices can reduce the risk that you will develop clinically diagnosed prostate cancer.

Some men instinctively start eating healthier as they mature, but it took a higher PSA read­ing (1.4 ng/mL) ten years ago for me to alter my diet in a healthier direction. My diet is not perfect, but it’s a huge improvement over what I consumed in my younger years. My last PSA test came in at 0.4 ng/mL…a 71% decrease in a ten-year period (PSA levels nor­mally rise with age).

If I had not had my PSA checked annually, I may have continued making poor dietary choices and may have developed prostate cancer by now. My father was diagnosed with it around age 75. He consumed a typical diet for his era, with a daily intake of red meat and high glycemic starches like potatoes, while never touching a vegetable or fruit. He set himself up perfectly to encourage prostate cancer growth and mutation.

Even for those who aren’t sure if they are making the proper food choices, laboratory tests like the Omega Score® test (a fatty acid profile) enable one to evaluate their diet and supplement pro­gram and make changes to opti­mize health. You are what you eat and what you assimilate does have a bearing on your health.

Five Stages of Prostate Cancer Progression

5 stages of prostate cancer progression

As prostate cancer progresses from Stage I to Stage IV, the cancer cells grow within the prostate, through the outer layer of the prostate into nearby tissue, and then to lymph nodes or other parts of the body.

A More Rational Approach

Most prostate tumors are very sensitive to their internal envi­ronment or what we prefer to call their “biological milieu.” We know this because when andro­gen-deprivation therapy is prop­erly administered, PSA levels can drop to near zero and prostate cancer cells die through the process of programmed cell death, a.k.a. apoptosis (Grossmann 2001; Nishiyama 2011).

However, it is not uncommon for prostate cancers to eventu­ally find other growth factors to fuel their continued prolifera­tion and the anti-proliferative and pro-apoptotic effects of androgen-deprivation therapy wear off, as evidenced by a continuously rising PSA that was once brought down to below 0.05 ng/mL by adequate­ly suppressing testosterone (Cox 2009; Singh PB 2008; Giton 2008; Dagvadorj 2007; Tu 2003; Ling 2005; Häggström 2000; Nishiyama 2011).

When a diagnosis of prostate cancer occurs in the setting of a rising PSA in the lower range (below 4 ng/dL ideally), Life Extension views this as an oppor­tunity for early intervention that might result in one’s body regain­ing control over tumor expansion.

We know that the drug Avodart® (dutasteride) lowers PSA levels by inhibiting the formation of dihydrotestosterone (DHT) (Arena 2013). Avodart® and its less potent cous­in Proscar® (finasteride) are 5ARIs (5-alpha reductase inhibi­tors) (Knezevich 2013). 5-alpha reductase is the enzyme that converts testosterone to DHT (Knezevich 2013). The effect of DHT on prostate cancer cell growth is five times greater than that of testos­terone (UCF 2013). By blocking DHT, drugs like Avodart® and Proscar® provide a unique opportunity to suppress tumor growth. At the same time, comprehensive adjunct protocols can be initiated that are designed to deprive tumor cells of growth factors or fuels, further inhibiting cancer growth and/or invasion.

For example, a recent study found that men taking finaste­ride for prostate cancer preven­tion were far more likely to benefit if they had lower estrogen levels prior to initiation of treatment with finasteride (Kristal 2012). This study clearly showed high concentra­tions of estrogen to be associat­ed with increased cancer risk. So much so that the elevated estrogen neutralized the prostate cancer prevention impact of finasteride. Life Extension has repeatedly warned aging men about the crit­ical need of achieving estrogen balance. One reason was our con­tinued observation of high estro­gen levels in newly diagnosed prostate cancer patients. Men can easily suppress elevated estrogen levels with aromatase-inhibiting therapies (Ta 2007).

So in response to a rising PSA and/or other indicators of prostate disease, men have a range of diag­nostic options to assess whether there is underlying malignancy and if there is, what may be help­ing to fuel it (such as elevated DHT or estrogen).

If non-invasive diagnostics indi­cate malignancy, a color Doppler ultrasound-guided biopsy can indicate whether it may be high-grade (Gleason score over 7 that requires treatment) or low-grade (Gleason score under 7 that may be controlled with comprehensive surveillance/intervention).

Some Life Extension mem­bers choose to attack a rising PSA as if there is already low-grade prostate cancer present, especial­ly if they suffer urinary symptoms relating to benign prostatic hyper­plasia (enlargement). In consulta­tion with their doctor, they may choose to take 0.5 mg of Avodart® daily (though it may not need to be taken every day) and simul­taneously introduce an arsenal of mechanistic approaches to restrain benign and/or tumor cell propagation and induce benign and/or tumor cell apoptosis.

The use of Avodart® or finaste­ride can shrink prostate gland vol­ume by 25% thus relieving benign symptoms, improve the accura­cy of a needle biopsy if this diag­nostic procedure is needed, and deprive tumor cells of one growth promoter, i.e. DHT (Cohen 2007; Nickel 2004).

A comprehensive arsenal of mechanistic approaches might involve healthy eating, high doses of specific nutrients (at least tem­porarily), hormone adjustment aimed at reducing DHT, insu­lin, prolactin and estrogen (but maintaining free testosterone [Yavuz 2008] in youthful ranges), and drugs like metformin and aspirin. If prolactin levels are elevated, the drug Dostinex® (carbergoline) can be used to suppress this cancer stimulating pituitary hormone.

I know this paradox has trou­bled aging men for decades, but according to a number of observa­tions and some published studies, low levels of testosterone seem to predispose men to prostate can­cer, including more high-grade Gleason score tumors. One expla­nation is that only low levels of testosterone are needed to con­vert into excess dihydrotestoster­one (DHT) (Nishiyama 2011). When prostate cells are deprived of their free testos­terone, they may mutate to over-respond to other growth vehicles such as estrogen, insulin-like-growth factor, and DHT (Kristal 2012).

Genetic Tests for Men Undergoing Prostate Biopsy

About half of US men diagnosed with prostate can­cer are classified as low-risk by use of conventional measures such as Gleason score (a form of tumor grading), the prostate-specific antigen test (PSA), and a physical exam (Genomic Health 2013). Nonetheless, nearly 90% of these low-risk patients will choose to undergo immediate aggressive treatment such as radical prostatectomy or radiation even though there is less than a 3% chance of deadly progression (Genomic Health 2013).

A new test called Oncotype DX is now available to physicians and their patients. It measures the level of expression of 17 genes across four biological path­ways to predict prostate cancer aggressiveness (Genomic Health 2013).

Test results are reported as a Genomic Prostate Score (GPS) ranging from 0 to 100; this score is assessed along with other clinical factors to clarify a man’s risk prior to treatment intervention (Genomic Health 2013). This multi-gene test can be used in conjunction with the needle biopsy sample taken before the prostate is removed, thereby providing the opportunity for low risk patients to avoid invasive treatments. According to the principal investigator of the validation study, “Individual biologi­cal information from the Oncotype DX prostate can­cer test almost tripled the number of patients who can more confidently consider active surveillance and avoid unnecessary treatment and its potential side effects” (Genomic Health).

The advantage of this test for those who choose the comprehensive surveillance program utilized by Life Extension members (which involves the use of several drugs, targeted nutrients, and adherence to healthy dietary patterns) is to provide greater assur­ance the right course of action is being followed.

For information about the Oncotype DX test, log on to www.oncotypedex.com.

Prolaris® is another genomic test developed to aid physicians in predicting prostate cancer aggressive­ness in conjunction with clinical parameters such as Gleason score and PSA (Myriad 2013).

Prolaris® measures prostate cancer tumor biology at the molecular level. By measuring and analyzing the level of expression of genes directly involved with can­cer replication, Prolaris® may be able to more accurately predict disease progression (Myriad 2013).

Prolaris® is a tool designed to measure the aggres­siveness of a patient’s cancers to better predict and stratify an individual’s relative risk of disease progres­sion within ten years (Myriad 2013). It may enable physicians to better define a treatment/monitoring strategy for their patients.

Prolaris® claims to be significantly more prognos­tic than currently used variables and provides unique additional information that can be combined with other clinical factors in an attempt to make a more accurate prediction of a patient’s cancer aggressiveness and therefore disease progression (Myriad 2013).

Prolaris® has been shown to predict clinical pro­gression in four different clinical cohorts, in both pre and post-treatment scenarios (Myriad 2013).

In the treatment of prostate cancer, Prolaris® is prognostic at the point of diagnosis and in the post-surgery setting (Myriad 2013).

At diagnosis, Prolaris® can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris® can define patients who appear clinically low-risk but have a more aggressive disease that requires more aggressive treatment.

Prolaris® testing is also well suited for use in post-prostatectomy patients that have higher risk features after surgery to better estimate their risk of disease recurrence and therefore adjust the level of monitoring or add additional therapy.

For more information about Prolaris®, log on to the company website: www.myriad.com

bening prostaic hyperplasia 

How Life Extension Differs From the Mainstream

A common approach to deal­ing with biopsied-confirmed low-grade prostate cancer is called “watchful waiting.” Under this scenario, PSA tests are performed at reasonable intervals and treat­ment decisions based on indica­tors of disease progression (or regression).

In the presence of persistently rising PSA and other markers, the patient and their doctor discuss wide ranges of treatment options ranging from surgical removal of the prostate gland, different forms of radiation, cryoablation, and/or androgen ablation to temporarily reduce PSA and buy more time. All of these treatment modalities have side effects to consider.

Instead of merely “watching” a PSA rise until risky therapies are required, we at Life Extension view a low-grade prostate cancer (or even a biopsy that reveals no cancer) as an opportunity to inter­vene aggressively with a multitude of non-toxic approaches that ben­efit one’s overall health. Success or failure is measured by monthly PSA testing, along with other tests to ensure that other growth fac­tors like insulin, estrogen, DHT, and prolactin are being adequately suppressed.

To clarify the point about a no cancer diagnosis, the accuracy of typical initial needle biopsies today is only around 75% (Taira 2010). So if your urologist tells you he has good news, i.e., the biopsy showed no tumor cells in your prostate gland, there may be a 25% chance you do have tumor cells, thus mak­ing the kinds of comprehensive intervention that benefits your entire body a rational choice.

So rather than “watchfully wait,” as your underlying disease may progress, we suggest com­prehensive intervention. The objective is to take away every route that enables tumor cells to propagate and escape confinement within the prostate gland.

For those who require a prostate biopsy, there are new (and expensive) genetic tests that may more accurately predict which tumors are aggressive and like­ly to metastasize and those that are so indolent that only minimal changes may be needed to keep control over them. If these genet­ic tests prove themselves in the clinical setting (outside the bias of company-sponsored clinical tri­als), intelligently using the results of these tests can spare many men from needless treatments and pro­vide information about genetic mutations to target in prostate cells that may enable better long-term control.

Enhanced Diagnostic Procedures

What patients should understand is the diagnosis of prostate cancer per ultrasound-guided biopsies is also related to the skill of the phy­sician performing the procedure, as well as the nature of the ultrasound (gray-scale versus color Doppler). CDU (color Doppler ultrasound) also indicates the degree of vascularity (angiogenesis) of the cancer, which if present is a factor associated with tumor aggressiveness. The more vascular the cancer the more aggressive it is. Dietary approaches, sup­plements, and medications to reduce angiogenesis should be consid­ered in the arsenal of how we prevent the emergence or evolution of clinically significant prostate cancer.

An additional emerging area that may allow a better understanding of clinically significant prostate cancer and clarify the issue of risk of high-grade prostate cancer with 5-alpha reductase inhibitor drugs like Avodart® and Proscar® involves replacing the transrectal ultrasound of the prostate (TRUSP) with MRI utilizing parameters such as DWI (diffusion weighted imaging) and the associated grading of DWI using the Apparent Diffusion Coefficient (ADC). Studies indicate a much higher specificity for the diagnosis of prostate cancer than TRUSP when DWI and ADC are used together (Shimamoto 2012; Ibrahiem 2012).

Our Enlarging Prostate Glands

Aging results in a proliferation of prostate cells that is technical­ly referred to as benign prostatic hyperplasia (BPH) (Gharaee-Kermani 2013). The graph­ic titled “The Development of Benign Prostatic Hyperplasia” depicts an advanced case of BPH with a constrict­ed urethra that would impede or block urine flow.

Symptoms associated with BPH include frequent urination and urinary hesitancy that can be especially troublesome at night (Gharaee-Kermani 2013). In severe cases obstruction of urine flow requires insertion of a catheter into the bladder via the penile urethra.

A major culprit involved in the benign over-proliferation of pros­tate cells is dihydrotestosterone (DHT) (Clark 2004). Drugs such as Avodart® (dutasteride) or Proscar® (finaste­ride) reduce DHT levels and shrink the size of an enlarged prostate gland, which reduces BPH symp­toms (Schmidt 2011). These drugs also lower PSA levels by almost 50%, which may reflect the mechanism(s) that explain why men taking these drugs have reduced overall pros­tate cancer risk (Kaplan 2002; Handel 2006; Nelson 2010). In two large studies, men taking Avodart® or Proscar® had about a 24% reduced risk of prostate cancer (Thompson 2003; Andriole 2010).

advanced case of BPH  

Men should know that testosterone is not the culprit behind prostate problems. Numerous studies suggest that youthful lev­els of testosterone do not increase prostate cancer risk (Tan 2004; Agarwal 2005; Gooren 2003; Morgentaler 2007; Rhoden 2008; Raynaud 2006). What happens in the aging man’s body, however, is that testosterone con­verts to estrogen and DHT, and these two testosterone metabolites have been shown to be involved in benign and malignant prostate disease. Fortunately, there are low-cost methods available to suppress DHT and estrogen in aging men, while maintaining youthful ranges of free testosterone.

Recall that PSA is not just a marker of prostate cancer, but functions as a tumor promoter by degrading barrier structures in the prostate gland that may contain isolated tumor cells.

Obstruction of urine flow  

What troubles Dr. Walsh and some other experts is that some of the men taking Avodart® or fin­asteride who do contract prostate cancer have been shown in two studies to develop more aggres­sive forms of the disease. They are so concerned that they warn men not to use these drugs for the purpose of prostate cancer prevention, as does the FDA.

On the flip side are propo­nents of these drugs who point out that Avodart® as well as Proscar® (finasteride) reduce prostate gland volume by such a degree that the ability to identify high-grade tumors via prostate biopsy is improved. So it does not appear that Avodart® or Proscar® causes more high-grade tumors. Instead, these drugs facilitate earlier detection of such cancers, which is another reason to con­sider taking them.

A frustration with needle biop­sies is that they miss as many as 20-30% of prostate cancers (Taira 2010; Rabbani 1998; Numao 2012). The larger one’s prostate gland, the easier it is to have the biopsy miss those sites that are malig­nant. The illustration titled “12-core Prostate Needle Biopsy” depicts a 12-core biopsy to show why a larger prostate gland makes it more difficult to detect malignant cells. So an advantage of shrinking one’s prostate gland using drugs like Avodart® or Proscar® is that if a needle biopsy is required, it may more accurately detect underlying malignancy (Kulkarni 2006).

In the December 2013 Life Extension magazine article titled The Avodart®-Proscar® Debate, there is compel­ling evidence that these drugs may reduce high-grade prostate cancer risk.

Another virtue to using 5-alpha reductase inhibitors (like Avodart® or Proscar®) is that in the presence of prostate cancer, PSA levels don’t decrease as much after these drugs are initiated (Kaplan 2002; Handel 2006; Nelson 2010).

Physicians using 5-alpha reduc­tase inhibitors should take into account the PSA-lowering effect of these agents by doubling the PSA lab value (Andriole 2006). Given that PSA decreases less in the presence of prostate cancer, the doubling of PSA will result in a higher value of PSA and will trigger the need for diagnostic investigations sooner.

What doctors have observed is that drugs like Avodart® or finaste­ride suppress PSA levels more effec­tively in men with benign prostate enlargement or low-grade prostate cancer. When PSA levels drop then start raising again, this indicates that the 5-alpha reductase inhibitor is reducing low-grade cells of ques­tionable clinical significance but is not affecting higher grade malig­nancies (Cohen 2007). This finding is another plus for using a 5-alpha reductase inhibitor as it can increase the sen­sitivity of the PSA test to reveal which men need aggressive diag­nostics such as needle biopsies.

12-core Prostate Needle Biopsy

12 core prostate needle boipsy 

This diagram depicts a 12-core needle biopsy of a prostate gland. Note how many areas of the prostate are missed during biopsy. In the PCPT (Prostate Cancer Prevention Trial) where only 6 core biopsies from 6 regions of the gland were obtained, the effect of Proscar® in reducing gland volume was to increase the ability to detect high-grade prostate cancer (Yavuz 2008; Redman 2008).

Why We Suggest Certain Drugs

When it comes to combat­ting cancer, Life Extension long ago learned that the initial treat­ment regimen should be aggres­sive enough to deprive tumor cells of an opportunity to mutate into forms that are resistant to future therapies. If we know of a rela­tively side effect-free drug that works via a single or multiple mechanisms to impede tumor sur­vival, we’re going to include it in our comprehensive surveillance program.

Let’s talk first about metfor­min. It was used in England in 1958 but did not make it into the United States until 199537 years later (Dowling 2011)! I am familiar with metformin because the FDA tried to have me incarcerated for recom­mending it as an anti-aging drug long before it was “approved” to treat type II diabetes.

What’s been happening over the last ten years is an explosion of published studies that consistently show that metformin reduces the risks of certain tumors and may be an effective cancer treatment (Hirsch 2009; Anisimov 2005; Vazquez-Martin 2011; Tomimoto 2008; Gotlieb 2008; Cantrell 2010; Libby 2009; Memmott 2010).

People ask me all the time, how can an anti-diabetic drug work so well against cancer? The encouraging news is that metfor­min functions via multiple mech­anisms to create a less favorable environment for tumor progres­sion (Evans 2005; Currie 2009; Nagi 1993; Choi 2013; Luo 2010; Ben Sahra 2011; Loubière 2013; Zakikhani 2008; Ben Sahara 2008; Ersoy 2008). We know that insulin (and glucose) increase the risk of many tumors (Parekh 2013). This is of partic­ular concern to obese men with prostate tumors. Metformin low­ers blood glucose and insulin lev­els. The sidebar titled “Anti-Cancer Actions of Metformin” reveals the multiple anti-cancer mechanism of metformin.

There are nutrients that can have similar effects such as stan­dardized green coffee extract (Ong 2013). We nonetheless suggest that a man with an elevated or rising PSA should ask his doctor to consider prescribing metformin. The start­ing dose can be 500 mg of extend­ed release (Metformin ER) taken with breakfast each day. Under the supervision of the patient’s local medical doctor, the dose can be increased to 500 mg ER taken at breakfast and at dinner. (Dose ranges for non-extended release metformin are 250-850 mg taken before no more than three meals a day.) Metformin is an inexpen­sive generic drug and can be taken along with nutrients (like green coffee extract) that similarly function to reduce glucose/insulin.

Metformin does more than slash tumor-promoting glucose/insulin levels. It also acts directly on cancer cells to induce apopto­sis and/or inhibit proliferation (Jalving 2010). Metformin does this conserving the process by which food is con­verted to energy (Choi 2013; Luo 2010; Ben Sahra 2011; Loubière 2013). Healthy cells react to metformin by adjusting their functions to use less energy. A cancer cell, on the other hand, that is forced to minimize energy consumption is less able to exhibit aggressive metastatic or prolifera­tive behavior (Dunlap 2012). In other scenarios, the energy stress caused by met­formin is sufficient to cause can­cer cell death.

The National Cancer Institute is sponsoring a clinical study where metformin will be tested to see if it can slow the progression of prostate cancer in men under­going active surveillance (watchful waiting) with low-grade tumors (Fleshner 2013). We hope the study design includes the measurement of 2-hour post-prandial (2 hours after meals) blood glucose levels as well as gly­cosylated hemoglobin (HbA1c) to ascertain that optimal dosing of study subjects has been achieved.

Anti-Cancer Actions of Metformin

Numerous studies show the anti-diabetic drug metformin can slow growth of existing cancers and decrease risk of developing new can­cers. Some studies show metformin may protect against prostate can­cer and aid in treatment. Here are some of its anti-cancer mechanisms:

  • Metformin reduces levels of glucose, insulin, and insulin-like growth factors that fuel tumor growth (Evans 2005; Currie 2009; Nagi 1993; Choi 2013).
  • Metformin activates a powerful molecule called AMPK (adenosine monophosphate-activated protein kinase) that sub­jects cancer cells to unique metabolic stresses not experienced by healthy tissues. (Activated AMPK promotes death [apoptosis] of malignant cells and prevents their development.) (Choi 2013; Luo 2010)
  • Metformin independently inhibits mTOR (mammalian target of rapamycin) that regulates cell growth, energy metabolism, cell motility, cell survival, and protein synthesis (Ben Sahra 2011; Loubière 2013).
  • Metformin mimics the benefits of a hormone called adiponectin in activating AMPK-dependent growth inhibition in prostate cancer cells (Zakikhani 2008).
  • Metformin blocks cancer cell reproductive cycles by decreasing levels of a growth-promoting protein called cyclin D1 (Ben Sahra 2008).
  • Metformin increases production of a protein (p27) that inhibits the cell division cycle (Ben Sahra 2008).
  • Metformin suppresses vascular endothelial growth factor (VEGF) thereby cutting off the blood supply to tumors (Ersoy 2008).

At a cancer conference in early 2013, the results of a study were reported of 22 men (medi­an age 64, median PSA 6 ng/mL) with confirmed prostate cancer that were given 500 mg of met­formin three times a day 41 days prior to surgery (prostatectomy). In response to metformin the men showed the expected reductions in glucose and insulin growth fac­tor-1 (IGF-1) blood levels, along with abdominal fat loss (Joshua 2012). What got the researchers excited was that compared to biopsied spec­imens, the surgically removed prostate glands showed a 32% reduction in a marker of cell pro­liferation (Ki-67) and a favorable alteration in a pathway tumor cells use to proliferate out of control (via mTOR) (Carlson 2012).

Knowledgeable members point out that curcumin interferes with these tumor growth pathways via similar mechanisms, which we at Life Extension have long been familiar with (Ravindran 2009). My argument for recommending metformin is that it should produce potent additive effects to curcumin. Moreover, we still don’t know what the upper dose limits are for metformin and/or curcumin for cancer treat­ment, so taking both may have some obvious advantages.

Furthermore, because met­formin is a drug, it tends to get more attention from research­ers, perhaps because it is easier to obtain funding for drug studies. A European study published this year showed that metformin was effective against advanced castra­tion-resistant prostate cancer. The doctors who conducted this study concluded:

To our knowledge, our results are the first clinical data to indicate that metformin use may improve PSA-recurrence free survival, distant metastasis-free survival, prostate cancer spe­cific mortality, overall survival and reduce the development of castration resistant prostate cancer in prostate cancer patients. Further vali­dation of metformin’s potential benefits is warranted (Spratt 2013).

Interestingly, men who are on androgen deprivation therapy to treat prostate cancer often show rising insulin levels that can stim­ulate tumor growth (Currie 2009; Hvid 2013). By tak­ing metformin, some of the side effects of androgen deprivation therapy can be mitigated, as was shown in this newly published European study.

So while nutrients like cur­cumin and green coffee extract and others may share functions that are similar to metformin, we cannot ignore the strong data showing specific benefits to low-cost metformin.

Another hormone that pros­tate tumors use to escape eradi­cation is prolactin (Dagvadorj 2007), and this can easily be suppressed by taking 0.25 mg to 0.5 mg of cabergoline (Dosintex®) two to three times weekly (Drugs.com 2013).

Aspirin functions in multi­ple ways to interfere with pros­tate cancer propagation and metastasis and it may induce genetic changes that facilitate apoptosis (Langley 2011). There is too much data about the potential role of aspirin as an adjuvant cancer treatment for men with rising PSAs not to use it.

Daily Use of Aspirin May Decrease Prostate Risks

Researchers studied 2,447 men over 12 years, examining them every other year. After adjusting for age, diabetes, hypertension, and other fac­tors, they found that men who took a daily aspirin or another NSAID (like ibuprofen) reduced their risk of moderate or severe urinary symptoms by 27% and lowered their risk of an enlarged prostate by 47%. Even more intriguing was the finding that men who consumed aspirin or another NSAID were 48% less likely to have an elevated level of prostate-spe­cific antigen (PSA) (St Sauver 2006).

Aspirin inhibits the cyclooxygenase (COX-1 and COX-2) enzymes, which are also involved in the arachidonic acid inflammatory path­way (Egan 2006; Wu 2003). COX-2 in particular is known to promote the proliferation of prostate cancer cells (Xu 2008).

Treat Yourself As If You Already Have Prostate Cancer

This protocol is supposed to be about prostate cancer prevention, and here I am talking about ther­apies overlooked by most doctors that may facilitate enhanced treat­ment outcomes.

The reason we can’t ignore treatments is that aging men should accept the reality that in all likelihood there are malignant cells in their prostate glands now. This makes it easier to consis­tently follow prevention programs that can reduce the risk that clini­cally diagnosed disease will ever manifest. It also keeps one on the lookout for non-toxic treatments that may also have preventative benefits.

As I have related in the past, when my PSA reading came back at 1.4 ng/mL in year 2003, I treat­ed it as if I had early stage pros­tate cancer by adopting healthier dietary choices and taking every nutrient and drug that had shown efficacy in prostate cancer preven­tion. Ten years later my PSA is 0.4 ng/mL.

I will remain on an aggressive prostate cancer treatment regimen and in the process reduce my risk for virtually every other age-relat­ed disease.

The protocol provides comprehensive approaches for the prevention of prostate cancer, including a comprehensive overview demon­strating the prostate cancer pre­vention benefits in response to Avodart® and finasteride. Men with any type of prostate malig­nancy may also benefit, as the pro­grams we advocate for prevention may also facilitate better overall treatment.

What if PSA Screen Detects a Potential Problem?

If an annual PSA screen reveals a potential problem, a man has an early opportunity to:

  1. Review state-of-the-art studies to establish his status regarding the presence of prostate cancer.
  2. Confirm the diagnosis and get a Gleason score reading by an expert in prostate cancer pathology.
  3. Utilize published nomograms and neural nets to present the patient probabilities of organ-confined prostate cancer, capsular penetration, or disease progression to seminal vesicles and/or lymph nodes.
  4. Obtain refined laboratory studies and imaging studies to confirm or refute the above.
  5. Sit down with a physician that is least biased on a particular procedure and discuss the pros and cons of all therapies, including active surveillance.
  6. Investigate and discuss all co-related illnesses that might have gone unrecognized but that play a role in stimulating prostate cancer growth.
 
Don’t Accept Archaic Diagnostics

The highly variable skills of the urologist performing TRUSP (tran­srectal ultrasound guided needle biopsy of the prostate) is of great con­cern when a biopsy is needed.

Too often the urologist uses the TRUSP to target the prostate gland per se, rather than abnormal areas within the prostate. Rarely do we see a dedicated TRUSP report that mentions all of the important find­ings that can and should be related by the urologist e.g., gland volume, PSA density, status of the capsule and seminal vesicles, as well as loca­tion of hypoechoic and hyperechoic lesions within the prostate. Using the TRUSP to target the prostate gland, and not the various lesions within the gland is akin to diluting a vintage wine with ice cubes. (For illustration and a description of a model TRUSP report, see Appendix F of the book A Primer on Prostate Cancer by Strum and Pogliano available from Life Extension Media by calling 1-800-544-4440 or log­ging on to www.lef.org)

The varying quality of the ultrasound device and whether it is a stan­dard gray-scale ultrasound or a color Doppler ultrasound is also significant. Color Doppler ultrasound, for instance, discloses patho­logic states of increased blood vessel growth (angiogenesis) that is associated with more clinically aggressive prostate cancer, which is often of a higher Gleason score (Strohmeyer 2001).

MRI (magnetic resonance imaging) using DWI (diffusion weighted imaging) will also add to understanding the risk a particular patient with prostate cancer faces. That’s because when color Doppler ultra­sound is combined with MRI-DWI, a predictive value regarding the level of aggressiveness of the prostate cancer may be established (Ibrahiem 2012).

In this manner, selecting only those men whose prostate cancers are most likely to be “bad actors” and who need invasive therapy can be accomplished, while sparing those men with cancers of low grade, which are often amenable to changes in lifestyle, diet, and use of sup­plements.